Capital Health Partners Acquires Calea (Canada) from Fresenius Kabi, Expanding Leadership in Home Infusion and TPN Pharmacy Services Across Canada

Capital Health Partners Inc. is pleased to announce the successful acquisition of the Canadian Calea business, a leading provider of home infusion and total parenteral nutrition (TPN) services, from Fresenius Kabi. This transaction marks a significant milestone in Capital Health Partners’ mission to transform and expand home-based healthcare across Canada.

With the addition of Calea to its group of companies—which includes Ontario Medical Supply (OMS) and Royal Drugs— Capital Health Partners is expanding leadership in Home Infusion, Total Parenteral Nutrition (TPN) Pharmacy Services and Medical Supply Distribution across Canada.

“Calea’s clinical leadership, national reach, and decades of experience make it a perfect fit for our vision,” said Yves Portelance, CEO of Capital Health Partners. “Together, we are building a stronger, more innovative healthcare network that delivers exceptional care directly to patients’ homes.”

A Strategic Step Forward

Calea’s integration will enhance Capital Health Partners’ ability to:

• Serve a broader patient population across Canada
• Expand clinical and logistical capabilities
• Drive innovation in home-based care delivery

This acquisition aligns with Capital Health Partners’ commitment to improving patient outcomes, supporting healthcare professionals, and advancing the future of home healthcare.

Commitment to Continuity and Collaboration

There will be no immediate changes to daily operations. Teams from OMS, Royal Drugs, and Calea will work closely to ensure a smooth and thoughtful integration process. Open communication, transparency, patient care, and employee support will remain top priorities throughout the transition.